1. ¹Department of Pulmonary Diseases, University Hospital Groningen, PO Box 30.001, 9700 RB Groningen, the Netherlands
2. ²Department of Pulmonary Diseases, Jeroen Bosch Hospital, PO Box 90.153, 5200 ME s Hertogenbosch, the Netherlands
3. ³Department of Pulmonary Diseases, St Antonius Hospital, PO Box 2500, 3430 EM Nieuwegein, the Netherlands
4. ⁴Department of Pulmonary Diseases, Vrije Universiteit Medical Center, PO Box 7057, 1007 MB Amsterdam, the Netherlands
5. ⁵Department of Pulmonary Diseases, Isala Clinics, PO Box 10.400, 8000 GK Zwolle, the Netherlands
6. ⁶Department of Pulmonary Diseases, Martini Hospital, PO Box 30.033, 9700 RM Groningen, the Netherlands

Correspondence: Dr HJM Groen, E-mail: h.j.m.groen@int.azg.nl

Received 9 July 2004; Revised 20 October 2004; Accepted 20 October 2004; Published online 14 December 2004.

Abstract

Response rate and toxicity of second-line therapy with docetaxel (75 mg m^-2) or docetaxel, irinotecan, and lenogastrim (60 mg m^-2, 200 mg m^-2, and 150 g m^-2 day^-1, respectively) were compared in 108 patients with stage IIIb–IV non-small-cell lung cancer. Addition of irinotecan to docetaxel does not improve response rate, and increases gastrointestinal toxicity.